D.J. Goldstein
Lilly Research Laboratories
Indianapolis
IN 46285-2128
USA
Name/email consistency: high
- Determination of pregnancy outcome risk rates after exposure to an intervention. Goldstein, D.J., Sundell, K.L., DeBrota, D.J., Offen, W.W. Clin. Pharmacol. Ther. (2001)
- Lanepitant, an NK-1 antagonist, in migraine prevention. Goldstein, D.J., Offen, W.W., Klein, E.G., Phebus, L.A., Hipskind, P., Johnson, K.W., Ryan, R.E. Cephalalgia (2001)
- Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Goldstein, D.J., Roon, K.I., Offen, W.W., Ramadan, N.M., Phebus, L.A., Johnson, K.W., Schaus, J.M., Ferrari, M.D. Lancet (2001)
- Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Goldstein, D.J., Wang, O., Todd, L.E., Gitter, B.D., DeBrota, D.J., Iyengar, S. Clin. Pharmacol. Ther. (2000)
- Olanzapine-exposed pregnancies and lactation: early experience. Goldstein, D.J., Corbin, L.A., Fung, M.C. J. Clin. Psychopharmacol (2000)
- Fluoxetine in medically stable, depressed geriatric patients: effects on weight. Goldstein, D.J., Hamilton, S.H., Masica, D.N., Beasley, C.M. J. Clin. Psychopharmacol (1997)